http://anthraxvaccine.blogspot.com/2022 ... while.htmlMonday, March 14, 2022
Pfizer CEO says 4th shot needed, while Europe's FDA says doing so risks "overloading the immune system" and might damage your immunity. Who would you trust?
Pfizer's Bourla says we need a 4th shot. Pfizer sold $36.8 billion dollars' worth of COVID vaccines in 2021, making its vaccine the top-selling pharmaceutical product in history. Pfizer has estimated its COVID vaccine sales for 2022 at $32 billion.
Albert Bourla says we need a 4th dose of his magic money-making elixir, but his company is also working on a universal coronavirus vaccine (a 2nd magic elixir), which we will only need once a year.
Albert Bourla, PhD, CEO of Pfizer, said a second booster shot of the COVID-19 vaccine is necessary for protection against infection, according to a March 13 interview with CBS News.
Dr. Bourla said the third dose of the COVID-19 vaccine provides protection from hospitalization and death, but "it's not that good against infections" and the protection is relatively short-lived. Pfizer is preparing data for the FDA about the need for a fourth dose.
"Many variants are coming," Dr. Bourla told CBS. "And omicron was the first one that was able to evade in a skillful way the immune protection that we were giving. But also, in all that the duration of the protection, it doesn't last very long.”
...In February, the CDC published a study showing the efficacy of booster shots of Pfizer-BioNTech and Moderna vaccines waned after about four months, but still provided significant protection from hospitalizations during the omicron surge.
Dr. Bourla also told CNBC that Pfizer is developing a vaccine that will protect against all COVID-19 variants, including omicron, for at least a year. He expects to review data from trials on the long-term vaccine by the end of the month.
But Dr. Marco Cavaleri, a top regulator at Europe's FDA, called the European Medicines' Agency (EMA), says this may weaken the immune response. According to Reuters:
The European Union's drug regulator on Tuesday expressed doubts about the need for a fourth booster dose of COVID-19 vaccine and said there is currently no data to support this approach as it seeks more data on the fast-spreading Omicron variant.
"While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy," the European Medicines Agency's Head of Vaccines Strategy, Marco Cavaleri, told a media briefing.
The EMA official raised concerns that a strategy of giving boosters every four months hypothetically poses the risk of overloading people's immune systems and leading to fatigue in the population.
Cavaleri also said more data on the impact of the new variant on vaccines and a better understanding of the evolution of the current wave were needed to decide whether an Omicron-specific vaccine was needed.
"It is important that there is a good discussion around the choice of the composition of the vaccine to make sure that we have a strategy that is not just reactive ... and try to come up with an approach that will be suitable in order to prevent a future variant," he said.
The EMA said it was currently in conversation with vaccine developers in case there is a need for an updated vaccine but added that any such change would need to be coordinated globally.
Posted by Meryl Nass, M.D. at 1:29 PM 1 comments
Sunday, March 13, 2022
Official documents reveal huge gap between what FDA and Pfizer would attest to, compared to what the public was told about the vaccine
The label for COMIRNATY is a legal document updated on 12/20/21:
1. CDC made the false claim on its website that anaphylactic reactions occur at rates approximately the same after COVID vaccines as other vaccines. I just looked for the citation and see the claim has recently been removed. Now, CDC informs us that "safeguards are in place" in case you do develop anaphylaxis after a COVID shot.
The Comirnaty label and CDC website make plain that administration of the vaccine is limited to only those facilities able to medically manage anaphylactic reactions. This is not the case for other vaccines.
A study from Harvard hospitals (where the CDC Director worked till Jan 2021) showed the rate of anaphylaxis, using standard criteria, in vaccinated employees, was about 50-100 times higher than the rate claimed by CDC, which happens to be the rate calculated by VAERS (in which underreporting by a factor of 10 to 100 is believed to occur). I wrote about this in the Defender in January 2021 and revealed how CDC used inappropriate and inadequate data to derive such a low rate.
2. While the CDC website suggests episodes of myocarditis are mild and resolve quickly, the label plainly states, "Information is not yet available about potential long-term sequelae."
3. CDC encourages vaccination during pregnancy. What the label says is, "available data on COMIRNATY administered to pregnant women are insufficient to inform vaccine associated risks in pregnancy."
4. It has been claimed that COMIRNATY and other vaccines could not possibly cause or stimulate cancer or cause fertility problems. What does the label say? "COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility."
Around the time that FDA gave the Pfizer vaccine an EUA at warp speed, on December 11, 2020, an EUA review memorandum was written, which I discuss below
1. Although people who had already had COVID were encouraged and sometimes forced to be vaccinated, the document states, "very few cases of confirmed COVID-19 occurred among participants with evidence of infection prior to vaccination. Therefore, available data are insufficient to make conclusions about benefit in individuals with prior SARS-CoV-2 infection."
2. Although FDA gave Pfizer an authorization to vaccinate everyone aged 16 and up on December 10, 2020, the document points out, "only one confirmed COVID-19 case was reported in this age group." In other words, there were no data to support efficacy in the 16 and 17 year olds. No wonder 4 members of the FDA advisory committee voted no, and one abstained from supporting authorization. My suspicion is that 16 and 17 year olds were needed in order to put COVID vaccines on CDC's recommended childhood schedule, despite lack of supporting data, so FDA pushed it through.
And sure enough, CDC had its Advisory Committee vote (13-1) to put the vaccine on the childhood schedule in August 2021. This will provide it a different form of liability protection, and opens the door to future mandates to attend school.
However, I just searched and failed to find evidence that the vaccine was actually added. Very interesting.
3. Even though the spectre of asymptomatic infections drove masks, social distancing, school closures, working from home, etc. etc., apparently FDA did not require Pfizer to test its vaccine to see if it prevented asymptomatic infection. The document states, "Data are limited to assess the effect of the vaccine against asymptomatic infection."
4. The entire point of vaccinating to achieve herd immunity was allegedly to prevent spread from person to person. How is it possible that neither FDA nor Pfizer sought out evidence that the vaccine prevented transmission? The report states, "Data are limited to assess the effects of the vaccine against transmission of SARS-CoV-2 from individuals who are infected despite vaccination."
5. The biggest concern of scientists everywhere, including Fauci, was the potential that the vaccine might cause enhanced coronavirus disease, a prooblem that had occurred occasionally with new vaccines and had occurred with a coronavirus vaccine prototype. LIsten to what the report says: one 'could' conduct such studies in future: "Available data do not indicate a risk of vaccine – enhanced disease, and conversely suggest effectiveness against severe disease within the available follow-up period. However, risk of vaccine-enhanced disease over time, potentially associated with waning immunity, remains unknown and needs to be evaluated further in ongoing clinical trials and in observational studies that could be conducted following authorization and or licensure."
Posted by Meryl Nass, M.D. at 9:48 PM 1 comments
Saturday, March 12, 2022
Look how many doses of vaccine the USG was contracting for/ NY Times Jan 2021
I am reposting this NYT article as it is one of several I blogged about last year regarding the large numbers of doses of COVID vaccines governments were buying, when they ought to have had no idea how much they would need...and certainly not 2.1 billion doses for the USA with resale forbidden. What did they know and when? Was the whole bloody pandemic an excuse to keep giving us "boosters" of something, and/or to create a reason we would need vaccine passports, to keep up with the boosters?
I can think of no benign explanations for this--if you know of one, please post it.
Thursday, January 28, 2021
USG buys too much vaccine. Governments Sign Secret Vaccine Deals: Here’s What They Hide/ NYT
Check out this NY Times article published today. The US government is buying much more vaccine than is needed for every American. But it also has signed contracts restricting the overseas sale of some of its purchases. So if it can't be sold, why is the government committed to buying so much? Is the plan to give everyone frequent boosters? The contracts are extremely secret.
https://www.nytimes.com/2021/01/28/worl ... rices.htmlMultibillion-dollar contracts give drug makers liability shields, patent ownership and leeway on delivery dates and pricing — and promises that much of it will not be made public.
When members of the European Parliament sat down this month to read the first publicly available contract for purchasing coronavirus vaccines, they noticed something missing. Actually, a lot missing.
The price per dose? Redacted. The rollout schedule? Redacted. The amount of money being paid up front? Redacted.
And that contract, between the German pharmaceutical company CureVac and the European Union, is considered one of the world’s most transparent.
Governments have poured billions of dollars into helping drug companies develop vaccines and are spending billions more to buy doses. But the details of those deals largely remain secret, with governments and public health organizations acquiescing to drug company demands for secrecy.
Just weeks into the vaccination campaign, that secrecy is already making accountability difficult. The drug companies Pfizer and AstraZeneca recently announced that they would miss their European delivery targets, causing widespread concern as dangerous virus variants spread. But the terms of their contracts remain closely guarded secrets, making it difficult to question company or government officials about either blame or recourse.
Available documents, however suggest that drug companies demanded, and received, flexible delivery schedules, patent protection and immunity from liability if anything goes wrong. In some instances, countries are prohibited from donating or reselling doses, a ban that could hamper efforts to get vaccines to poor countries.
Governments are cutting at least three types of vaccine deals: Some are buying directly from pharmaceutical companies. Others are buying through regional bodies like the European Union or the African Union. Many will turn to the nonprofit Covax program, an alliance of more than 190 countries, which is buying from the drug makers with an eye toward making vaccines available worldwide, especially to poor countries free or at reduced cost. Some governments have signed deals with manufacturers and Covax alike.
The United States has secured 400 million doses of the Pfizer-BioNTech and Moderna vaccines, enough for 200 million people, and is close to arranging 200 million additional doses by summer, with options to buy up to 500 million more. It also has advance purchase agreements for more than 1 billion doses from four other companies whose inoculations do not yet have U.S. regulatory approval.
The European Commission, the European Union’s executive branch negotiating on behalf of its 27 member states, has nearly 2.3 billion doses under contract and is negotiating for about 300 million more, according to data collected by UNICEF and Airfinity, a science analytics company...
Covax says it has agreements for just over 2 billion vaccine doses although it, too, is keeping its contracts secret. Only about a dozen of the 92 countries that qualify for vaccine subsidies under the alliance have managed to secure separate deals with individual companies, for a combined 500 million doses.
The CureVac contract, for example, prohibits European countries from reselling, exporting or donating doses — including to Covax — without permission from the company. Some contracts in the United States have similar restrictions...
Companies Get Liability Protection
In the United States, drug companies are shielded from nearly all liability if their vaccines don’t work or cause serious side effects. The government covered Covid-19 drug makers under the PREP Act, a 2005 law intended to speed up access to medicine during health emergencies.
That means that people cannot sue the companies, even in cases of negligence or recklessness. The only exceptions are cases of proven, “willful misconduct.”
Drug companies are seeking similar liability waivers in negotiations with other countries... The CureVac-E.U. contract does shield the company from significant liability, but with exceptions. Those exceptions are redacted...
Posted by Meryl Nass, M.D. at 9:12 PM 6 comments
Best